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Triflusal is a platelet aggregation inhibitor chemically related to acetylsalicylic acid, which
is used for the prevention and/or treatment of vascular thromboembolisms, which acts
as a prodrug. Actually, after oral administration it is absorbed primarily in the small
intestine, binds to plasma proteins (99%) and is rapidly biotransformed in the liver
into its deacetylated active metabolite 2-hydroxy-4-trifluoromethylbenzoic acid (HTB).
In healthy humans, the half-life of triflusal is ca. 0.5 h, whereas for HTB it is ca.
35 h. From a pharmacological point of view, it is interesting to note that HTB is itself
highly active as a platelet anti-aggregant agent. Indeed, studies on the clinical profile
of both drug and metabolite have shown no significant differences between them. It
has been evidenced that HTB displays ability to induce photoallergy in humans. This
phenomenon involves a cell-mediated immune response, which is initiated by covalent
binding of a light-activated photosensitizer (or a species derived therefrom) to a protein.
In this context, small proteins like ubiquitin could be appropriate models for investigating
covalent binding by means of MS/MS and peptide fingerprint analysis. In previous work,
it was shown that HTB forms covalent photoadducts with isolated lysine. Interestingly,
ubiquitin contains seven lysine residues that could be modified by a similar reaction. With
this background, the aim of the present work is to explore adduct formation between the
triflusal metabolite and ubiquitin as model protein upon sunlight irradiation, combining
proteomic and photophysical (fluorescence and laser flash photolysis) techniques.
Photophysical and proteomic analysis demonstrates monoadduct formation as the
major outcome of the reaction. Interestingly, addition can take place at any of the
ε-amino groups of the lysine residues of the protein and involves replacement of the
trifluoromethyl moiety with a new amide function. This process can in principle occur
with other trifluoroaromatic compounds and may be responsible for the appearance of
undesired photoallergic side effects.
Keywords: covalent binding to protein, fluorescence, laser flash photolysis, lysine, mass spectrometry,
metabolite, photoallergy
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INTRODUCTION
Triflusal (Figure 1) is a platelet aggregation inhibitor chemically
related to acetylsalicylic acid, which is used for the prevention
and/or treatment of vascular thromboembolisms (McNeely and
Goa, 1998; Gonzalez-Correa and De La Cruz, 2006). Additionally,
triflusal increases nitric oxide synthesis in neutrophils, leading to
an increased vasodilator potential (Matías-Guiu et al., 2003).
From a clinical standpoint, triflusal shows similar efficacy to
aspirin in preventing stroke, but the former is associated with a
reduced risk of hemorrhagic complications. Structurally, it differs
from the latter in having a trifluoromethyl moiety at position
4 (Matías-Guiu et al., 2003; Gonzalez-Correa and De La Cruz,
2006).
Actually, triflusal acts as a prodrug since after oral
administration, it is absorbed primarily in the small intestine,
binds to plasma proteins (99%) and is rapidly biotransformed
in the liver into its deacetylated active metabolite 2-hydroxy-
4-trifluoromethylbenzoic acid (HTB, Figure 1) (Ramis et al.,
1991; McNeely and Goa, 1998; Cho et al., 2003) In healthy
humans, the half-life of triflusal is ca. 0.5 h, whereas for HTB
it is ca. 35 h (Gonzalez-Correa and De La Cruz, 2006). From a
pharmacological point of view, it is interesting to note that HTB
is itself highly active as a platelet anti-aggregant agent. Indeed,
studies on the clinical profile of both drug and metabolite have
shown no significant differences between them (Ramis et al.,
1991).
Although their side effects are mainly gastrointestinal, it has
been evidenced that both triflusal and HTB display ability to
induce photoallergy in humans (Serrano et al., 1987; Lee et al.,
1999, 2001; Nagore et al., 2000). This phenomenon involves a
cell-mediated immune response, which is initiated by covalent
binding of a light-activated photosensitizer (or a species derived
therefrom) to a protein, a process known as haptenation (Ariza
et al., 2011). Interestingly, although aspirin presents a similar
chemical structure, it is not associated with photosensitivity
disorders. Therefore, as mentioned above, the trifluoromethyl
group at position 4 present in triflusal and HTB should be
responsible for the photosensitizing properties of the molecule
(Bosca et al., 2001; Caffieri et al., 2007; Montanaro et al., 2009).
Ubiquitin is a small (8.5 KDa) regulatory protein, with 76
amino acids, present in all eukaryotic cells, which was discovered
in the early 1970s (Pickart and Eddins, 2004; Herrmann et al.,
2007; Hochstrasser, 2009).
FIGURE 1 | Chemical structures of triflusal and its metabolite HTB.
Covalent ubiquitination is a major regulatory post-
translational process, involving attachment of the ubiquitin
to lysine residue/s on a substrate protein or on another ubiquitin
molecule, leading to mono or polyubiquitination (Dikic et al.,
2009; Suryadinata et al., 2014). Thus, monobiquitination can
modify protein activity and localization by endocytosis, cell-cycle
control or lysosomal targeting (Dikic et al., 2009), whereas
polyubiquitination is implicated in DNA repair and immune
signaling (Dikic et al., 2009; McIntyre and Woodgate, 2015).
Besides, the discovery that ubiquitin chains target proteins to the
proteasome, which degrades and recycles proteins, was honored
with the Nobel Prize in chemistry in 2004.
Moreover, ubiquitin does not have a well-defined active site
although it binds to the so-called ubiquitin binding sites, which
are modular protein domains that non-covalently bind ubiquitin
(Hicke et al., 2005; Hurley et al., 2006; Dikic et al., 2009) and
reveal information about the functionality and the mechanism of
intermolecular regulation.
In this context, small proteins like ubiquitin could be
appropriate models for investigating covalent binding by means
of MS/MS and peptidic fingerprint analysis (Jeram et al., 2009;
Hong et al., 2015; Ramirez et al., 2015). In previous work, it
was shown that HTB forms covalent photoadducts with isolated
lysine and polylysine (Montanaro et al., 2009). Interestingly,
ubiquitin contains seven lysine residues (Lys6, Lys11, Lys27,
Lys29, Lys33, Lys48, and Lys 63) that could be modified by a
similar reaction.
With this background, the goal of the present work is to
identify possible adduct formed between the triflusal metabolite
and ubiquitin as model protein, upon sunlight irradiation,
combining proteomic and photophysical (fluorescence and laser
flash photolysis) techniques.
MATERIALS AND METHODS
Materials and Solvents
HTB was purchased from WAKO (Osaka, Japan) and was
used without further purification; n-butylamine and bovine
ubiquitin, whose sequence is identical to the human protein,
were provided from Sigma–Aldrich (Steinheim, Germany).
Phosphate buffered saline solution (PBS, pH = 7.4, 0.01 M)
was prepared by dissolving Sigma tablets in the appropriate
amount of deionized water. Sephadex G-25 columns (PD-10)
were acquired from Amersham Pharmacia Biotech (UK).
Dichloromethane and ethyl acetate were from Scharlab
(Sentmenat, Spain).
Photoaddition of HTB to Ubiquitin
Solutions containing HTB (5 × 10−5 M) and ubiquitin
(5 × 10−5 M) in PBS were incubated 1 h in the dark.
Samples were then irradiated for 1 h (18.9 J/cm2) under
the sunlight. For all photophysical studies, the photoadduct
was separated from the protein using guanidine chloride
and disposable Sephadex G-25 columns (PD-10) (Amersham
Pharmacia Biotech, UK) equilibrated with PBS and the final
product was further lyophilized at −55◦C for 16 h. Control
Frontiers in Pharmacology | www.frontiersin.org 2 August 2016 | Volume 7 | Article 277
fphar-07-00277 August 25, 2016 Time: 14:45 # 3
Nuin et al. Photosensitivity to Triflusal
included drug–protein mixture kept in the dark and ubiquitin
without irradiation.
Synthesis of HTB-n-Butylamine Adduct
A mixture of HTB (150 mg, 0.73 mmol) and n-butylamine
(720 µL, 7.3 mmol) dissolved in deaerated PBS solution
(20 mL) was placed in quartz tubes and irradiated overnight
by means of a multilamp photoreactor equipped with six lamps
(Hitachi, F15T8/BL) with a maximal output at ca. 300 nm
(Gaussian distribution). The crude product was dissolved in
ethyl acetate, washed with 1 M HCl and brine, dried over
MgSO4 and concentrated under vacuum. The residue was washed
with dichloromethane several times to get HTB-butylNH2 as
a white solid (94 mg, 63%). 1H NMR (300 MHz, CD3OD):
δ 0.98 (t, J = 7.3 Hz, 3H), 1.38–1.45 (m, 2H), 1.56–1.66
(m, 2H), 3.32–3.40 (m, 2H), 7.29 (dd, J = 8.2 Hz and
1.6 Hz, 1H), 7.34 (d, J = 1.6 Hz, 1H), 7.93 (d, J = 8.2 Hz,
1H); 13C NMR (75 MHz, CD3OD): δ 14.2, 21.2, 32.5, 40.9,
116.4, 117.0, 118.5, 131.9, 142.4, 163. 0 169.1, 173.0. Exact
mass: m/z found, 236.0922 calculated for C12H14NO4 (M-H)+
236.0928.
Laser Flash Photolysis Experiments
Laser flash photolysis (LFP) experiments were carried out
with a pulsed XeCl excimer laser (λexc = 308 nm, ca. 17
ns pulse width, <100 mJ per pulse). In general, samples
received between 1 and 3 pulses for all the kinetic experiments.
A pulsed Lo255 Oriel Xenon lamp was used as detecting
light source. The observation wavelength was selected with a
77200 Oriel monochromator, and the signal amplified by an
Oriel photomultiplier tube (PMT) system made up of a 77348
side-on tube, 70680 housing and a 70705 power supply. The
signal was registered with a TDS-640A Tektronix oscilloscope
and subsequently transferred to a personal computer. The
absorbance of the solutions was adjusted at ca. 0.21 at the
excitation wavelength. All transient spectra were recorded at
room temperature using 10 mm × 10 mm quartz cells with
4 mL capacity and were bubbled for 15 min with N2 before
acquisition.
Fluorescence Measurements
Steady-state fluorescence experiments were carried out using
a Photon Technology International (PTI, Germany) LPS-
220B spectrofluorometer, equipped with a monochromator
in the range of 200–700 nm. Time-resolved fluorescence
measurements were performed with a Time Master
fluorescence lifetime spectrometer TM 2/2003 from PTI,
using a hydrogen/nitrogen flash lamp as the excitation source.
The kinetic traces were fitted by monoexponential decay
functions, using a deconvolution procedure to separate them
from the lamp pulse profile. Emission measurements were
performed in the region of 330–600 nm. The absorbance
of the solutions was adjusted at ca. 0.08 at 308 nm. All
measurements were performed at room temperature using
10 mm × 10 mm quartz cells of 4 mL capacity, under aerobic
conditions.
Mass Spectrometry Analysis of
HTB-Modified Ubiquitin by MALDI-TOF
Solutions containing HTB (5× 10−5 M) and ubiquitin (5× 10−6
M) in PBS were incubated 1 h in the dark, after which they
were exposed to sunlight (doses of UVA light of 18.9 J/cm2).
Incubation mixtures were directly mixed with the matrix and
applied to the MALDI-TOF analysis on an Autoflex III MALDI-
TOF-TOF mass spectrometer (Bruker), operated in the positive
mode as previously described (Renedo et al., 2007; Oeste et al.,
2011).
Protein Digestion and LC-ESI-MS/MS
Analysis
Solution containing HTB (5 × 10−5 M) and ubiquitin
(5 × 10−6 M) in PBS was incubated 1 h in the dark
and irradiated by sunlight. The samples were enzymatically
digested into smaller peptides using trypsin. Subsequently, these
peptides were analyzed using nanoscale liquid chromatography
coupled to tandem mass spectrometry (nano LC-MS/MS).
Briefly, 20 µg of sample were taken (according to Qubit
quantitation) and the volume was set to 20 µL. Digestion
was achieved with sequencing grade trypsin (Promega, trypsin:
protein ratio 1:20 w/w) V = 64 µL, overnight 37◦C.
Digestion was stopped with 7 µL 10% TFA (trifluoroacetic
acid). The final peptide mixture was at a concentration ca
0.5 µg/µL.
Next, 5 µL of sample were loaded onto a trap column
(NanoLC Column, 3 µ C18 CL, 100 umx 15 cm; Nikkyo)
and desalted with 0.1% TFA at 2 µL/min during 10 min.
The peptides were then loaded onto an analytical column (LC
Column, 3 µ C18 CL, 75 umx12 cm, Nikkyo) equilibrated
in 5% acetonitrile 0.1% formic acid. Elution was carried out
with a linear gradient of 5–40% B in A for 30 min (A:
0.1% formic acid; B: acetonitrile, 0.1% formic acid) at a
flow rate of 300 nL/min. Peptides were analyzed in a mass
spectrometer nanoESI qQTOF (5600 TripleTOF, ABSCIEX). The
tripleTOF was operated in information-dependent acquisition
FIGURE 2 | UV-Vis spectra of phosphate buffer solutions of HTB
(black), ubiquitin (violet), HTB-ubiquitin adduct (green) and
HTB-ButylNH2 adduct (red).
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FIGURE 3 | (Top) Steady-state fluorescence (λexc = 308 nm) of phosphate
buffer solution of HTB (black line), sunlight irradiated HTB-ubiquitin (1:1) after
sephadex filtration (green line) or non-irradiated HTB-ubiquitin (1:1) after
sephadex filtration (blue line), and HTB-butylNH2 adduct (red line). (Bottom)
Corresponding decays.
FIGURE 4 | Normalized transient absorption spectra of HTB (black
line), HTB/ubiquitin 1:1 (blue line), HTB-ubiquitin (green line) and
HTB-butylNH2 (red line) adducts in phosphate buffer N2-flushed
solutions, 0.5 µs after the laser pulse. Inset: normalized decay traces of
HTB /ubiquitin 1:1 (blue) and HTB-ubiquitin adduct (green).
mode, in which a 0.25-s TOF MS scan from 350 to 1250
m/z was performed, followed by 0.05-s product ion scans
from 100 to 1500 m/z on the 10 most intense 2–5 charged
ions.
FIGURE 5 | Photoadduct HTB-butylNH2 formation.
SCHEME 1 | Proposed mechanism of HTB-ubiquitin adduct formation.
ProteinPilot v4.5. (ABSciex) search engine default parameters
were used to generate peak list directly from 5600 TripleTOF wiff
files. The obtained mgf was used for identification with MASCOT
(v 4.0, Matrix- Science). Database search was performed on
Home Made (includes sequence of interest and the contaminants
described in Expasy). Searches were done with tryptic specificity
allowing one missed cleavage and a tolerance on the mass
measurement of 75 ppm in MS mode and 0.6 Da in MS/MS
mode. Oxidation of Met and deamidation of Asn and Gln as
variable modifications. HTB modification was set as variable
for K, S, T.
RESULTS AND DISCUSSION
Sunlight irradiation of buffered aqueous solutions of HTB
(5 × 10−5 M, Figure 1) and ubiquitin (1:1 molar ratio)
was performed at noon in Valencia (Spain, July). Then, the
protein material was separated from the free metabolite by
gel-filtration chromatography (Sephadex). The high-molecular
weight fraction was examined spectroscopically to reveal the
presence of a covalently linked chromophore. As a control
a 1:1 solution of HTB:ubiquitin was kept in the dark and
filtered by Sephadex. This way the comparison between
irradiated and non-irradiated samples would inform about the
formation of a covalent adduct between the metabolite and the
protein.
A first approach was based on UV-Vis spectrophotometry,
so the absorption spectrum of the obtained proteinaceous
fraction was registered together with those of ubiquitin
and HTB for comparison. The protein alone in solution
showed a band with a maximum at 270 nm and no
significant absorption at λ>300 nm (Figure 2, violet line);
by contrast HTB displayed a UVB-band centered at 300 nm
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FIGURE 6 | MALDI-TOF spectra of HTB-ubiquitin (10:1) kept in the dark (Top) or solution after 30 min of sunlight irradiation (Bottom).
TABLE 1 | Identification of HTB-modified peptide by MS/MS spectrometry.
Peptide adduct ID Observed precursor ion
(m/z)
Charge (z) Mr (exp) Mr (calcd) Sequence Adduct site
1 715.7316 2 1428.7316 1428.7323 1MQIFVK#TLTGK11 K6
2 818.0825 3 2451.2257 2451.2268 7TLTGK#TITLEVEPSDTIENVK27 K11
3 717.6962 3 2150.0668 2150.0630 12TITLEVEPSDTIENVK#AK29 K27
4 844.3987 2 1686.7828 1686.7849 30 IQDK#EGIPPDQQR42 K33
5 755.8790 2 1509.7434 1509.7463 43LIFAGK#QLEDGR54 K48
6 765.3953 3 2293.1641 2293.1590 55TLSDYNIQK#ESTLHLVLR72 K63
(Figure 2, black line). Interestingly, the irradiated and filtered
HTB:ubiquitin solution clearly exhibited an absorption peaking
at 310 nm (Figure 2, green line), whereas no UVB-band
was observed for the non-irradiated and filtered sample
(see Supplementary Material). This result points toward the
formation of a covalent adduct between the protein and the
metabolite.
To get further insight, steady-state and time-resolved
fluorescence experiments were conducted. At the excitation
wavelength of 308 nm, HTB emission was detected at ca.
405 nm in agreement with previous reports, (Bosca et al., 2001;
Montanaro et al., 2009) whereas a red shifted fluorescence
spectrum, with λem at ca. 420 nm, was obtained for the irradiated
and filtered HTB-ubiquitin sample (Figure 3 top, green line). No
emission was detected for the control solution kept in the dark
(Figure 3 top, blue line). Moreover, time-resolved experiments
revealed different lifetimes for the HTB and HTB-ubiquitin
samples, τ being of ca. 9.5 and 13.5 ns, respectively (Figure 3
bottom, black and green lines).
Additional spectroscopic studies of the covalent adduct
between HTB and ubiquitin were performed by nanosecond
LFP using a 308 nm XeCl excimer laser for excitation. The
transient spectra registered for a nitrogen-flushed solution of
HTB alone or irradiated and filtered HTB-ubiquitin in phosphate
buffer solutions are shown in Figure 4. The HTB-ubiquitin
adduct exhibited a transient absorption centered at 520 nm, a
wavelength close to that observed for the HTB triplet excited
state at λTT of ca. 500 nm (Bosca et al., 2001; Montanaro et al.,
2009).
Thus, detection of a spectroscopic response for the high
molecular weight fraction of the irradiated HTB:ubiquitin
solution evidenced the formation of a covalent photoadduct.
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FIGURE 7 | ESI-MS/MS spectra and fragmentation pathway of the HTB-modified peptide 4.
Furthermore, the spectral similarities between the free
metabolite and this proteinaceous fraction indicated the
presence of a HTB-like chromophore in the modified ubiquitin
biomolecule.
Thus, based on the previous studies that have established
photoaddition of HTB at the ε-amino group of lysine,
(Montanaro et al., 2009) the model compound (HTB-
butylNH2, Figure 5) was synthesized by UVB-irradiation
of a phosphate buffer solution of n-butylamine and HTB.
Photoadduct HTB-butylNH2 was obtained as main product
in 63% yield and fully characterized by NMR and HRMS (see
Supplementary Material). The spectroscopic characterization
of this model compound in phosphate buffer revealed a
strong analogy between its photobehavior and that of
HTB-ubiquitin photoadduct. Indeed, it displayed the
same UVB absorption maximum (Figure 2, red line), a
coincident fluorescence emission and lifetime (Figure 3),
as well as an identical transient absorption spectrum
(Figure 4).
Altogether, these results support formation of a HTB-
ubiquitin adduct through photoaddition at the ε-amino group
of lysine (Scheme 1). To obtain more precise structural
information, the photoreactivity of HTB with the whole
ubiquitin biomolecule was addressed by MALDI-TOF and
HPLC-nanoESI analysis. Comparison between the MALDI-
TOF spectra of sunlight irradiated solutions of ubiquitin
alone (5 × 10−5 M, m/z 8599) and HTB-ubiquitin (10:1)
mixture revealed the appearance of a new peak at m/z 8763
that corresponds to an increment of 164 amu (Figure 6),
compatible with L(-H). Similar results were obtained for
1:1 ratio. Next, incubation mixtures were filtered to remove
excess HTB and trypsin digestion followed by HPLC-MS/MS
was performed in order to investigate the modified peptide
sequence and to undertake a detailed characterization of the
HTB-ubiquitin adduct. Full scan, as well as fragmentation,
data files were analyzed by means of the Mascot R© database
search engine (Matrix Science, Boston, MA, USA) and by
entering variable modifications that take into account the
main nucleophilic sites able to react with the trifluoromethyl
group of HTB, i.e., Lys, Thr and Ser, (Caffieri et al., 2007;
Montanaro et al., 2009). Results confirmed identification of six
HTB-ubiquitin derived peptide adducts: 1MQIFVKTLTGK11,
7TLTGKTITLEVEPSDTIENVK27, 12TITLEVEPSDTIENVKAK
29, 30IQDKEGIPPDQQR42, 43LIFAGKQLEDGR54, 55TLSDY
NIQKESTLHLVLR72 (all peptides have one missed cleavage at
Lys), their related data are summarized in Table 1.
Thus, the modification site of each peptide was assessed by
tandem mass experiments on the trypsin digests. The MS/MS
fragmentation was achieved by selecting the precursor ions
given in Table 1. The peptide sequence well agreed with
the y and b ion series (see Supplementary Material). Here,
the case of fragment 4, namely 30IQDKEGIPPDQQR42, is
discussed as an example (Figure 7); further information on
the others fragments is given in the Supplementary Material.
The MS/MS fragment ions showed an unmodified y ion series
from y1 to y9, whereas an increment of m/z 292 L(-H)-Lys(-
H2O) was detected between y9 to y10. Accordingly, the b
ion series suffered the same increase from b3 to b4. Thus,
the modified amino acid is the Lys 33. Examination of the
other five tryptic peptides confirms that Lys is the main site
for the adduct formation with modifications detected at K6,
K11, K27, K48, and K63. It should be mentioned that no
diagnostic y and b fragment ions were found for Lys 27 and
29; however, detection of peptide 3 points toward formation
Frontiers in Pharmacology | www.frontiersin.org 6 August 2016 | Volume 7 | Article 277
fphar-07-00277 August 25, 2016 Time: 14:45 # 7
Nuin et al. Photosensitivity to Triflusal
of an adduct at site 27, which represents a missed cleavage due to
the bulky L substituent that likely hinders trypsin ability to cleave
at this site.
CONCLUSION
Irradiation of HTB, the active metabolite of triflusal, in
the presence of ubiquitin under sunlight gives rise to
covalent photobinding. Photophysical and proteomic analysis
demonstrate that although the main product found is a
monoadduct, the reaction take places at all the ε-amino groups
of the lysine residues of the protein and involves replacement
of the trifluoromethyl moiety with a new amide function.
Concentrations of both drug and protein used in the present work
are compatible with those present in blood plasma. Therefore, it
is expected that immunologic reactions occur in patients under
triflusal therapy in combination with sunlight exposure. This
process can in principle occur with other trifluoroaromatic
compounds and may be responsible for the appearance of
undesired photoallergic side effects.
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